​

Travere Therapeutics (TVTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TVTX Stock Forecast

Travere Therapeutics (TVTX) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $30.00, with a high of $33.00 and a low of $27.00. This represents a 101.07% increase from the last price of $14.92.

$5 $11 $17 $23 $29 $35 High: $33 Avg: $30 Low: $27 Last Closed Price: $14.92

TVTX Stock Rating

Travere Therapeutics stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (82.35%), 3 Hold (17.65%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 17 3 14 0 Strong Sell Sell Hold Buy Strong Buy

TVTX Price Target Upside V Benchmarks

TypeNameUpside
StockTravere Therapeutics101.07%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--14
Avg Price Target--$18.79
Last Closing Price$14.92$14.92$14.92
Upside/Downside--25.94%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 253112--16
Mar, 253112--16
Feb, 253112--16
Jan, 253112--16
Dec, 243102--15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 31, 2024Liisa BaykoEvercore ISI$33.00$17.5088.57%121.18%
Oct 21, 2024Mohit BansalWells Fargo$27.00$17.8751.09%80.97%
Oct 10, 2024Liisa BaykoEvercore ISI$30.00$18.0766.02%101.07%
Oct 09, 2024Jason ZemanskyBank of America Securities$20.00$15.2131.49%34.05%
Oct 01, 2024Carter GouldBarclays$18.00$13.9928.66%20.64%
Sep 27, 2024Vamil DivanGuggenheim$23.00$15.0452.93%54.16%
Sep 27, 2024Ed ArceH.C. Wainwright$18.00$15.0419.68%20.64%
Sep 27, 2024Greg HarrisonBank of America Securities$18.00$14.0128.48%20.64%
Sep 10, 2024Ed NashCanaccord Genuity$23.00$12.7081.10%54.16%
Sep 09, 2024Vamil DivanGuggenheim$12.50$6.3198.10%-16.22%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 11, 2025ScotiabankOutperformOutperformhold
Jan 29, 2025Cowen & Co.BuyBuyhold
Jan 14, 2025GuggenheimBuyBuyhold
Oct 29, 2024Cowen & Co.BuyBuyhold
Oct 21, 2024Wells FargoSector OutperformSector Outperformhold
Oct 21, 2024Wells FargoBuyOverweightupgrade
Oct 16, 2024WedbushSector OutperformSector Outperformhold
Oct 16, 2024ScotiabankOutperforminitialise
Oct 10, 2024Evercore ISIOutperformOutperformhold
Oct 09, 2024WedbushOutperformOutperformhold

Financial Forecast

EPS Forecast

$-10 $-7 $-4 $-1 $2 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.56$-3.01$-4.37$-1.50$-4.08----
Avg Forecast$-1.45$-3.01$-4.48$-1.62$-3.66$-1.13$0.60$1.11$1.88
High Forecast$-1.08$-2.24$-3.17$-1.39$-3.54$-0.39$2.59$3.24$2.67
Low Forecast$-2.20$-4.59$-6.86$-1.79$-3.82$-1.75$-0.64$0.40$0.70
Surprise %145.52%--2.46%-7.41%11.48%----

Revenue Forecast

$100M $290M $480M $670M $860M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$198.32M$227.49M$212.02M$145.24M$233.18M----
Avg Forecast$198.95M$225.72M$208.36M$195.51M$230.58M$342.48M$478.46M$630.10M$780.85M
High Forecast$279.02M$316.57M$293.80M$198.06M$243.97M$415.94M$488.58M$833.66M$1.03B
Low Forecast$159.94M$181.47M$161.65M$193.14M$220.79M$266.55M$468.34M$325.75M$403.68M
Surprise %-0.31%0.78%1.76%-25.71%1.13%----

Net Income Forecast

$-500M $-350M $-200M $-50M $100M $250M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-169.43M$-180.09M$-278.48M$-111.40M$-321.55M----
Avg Forecast$-107.37M$-142.95M$-176.32M$-376.33M$-273.28M$-113.69M$41.94M$117.12M$139.77M
High Forecast$-80.01M$-114.36M$-141.05M$-301.07M$-262.54M$-29.06M$191.99M$240.53M$198.47M
Low Forecast$-163.55M$-171.54M$-211.58M$-451.60M$-284.02M$-129.88M$-47.47M$29.42M$52.01M
Surprise %57.80%25.98%57.94%-70.40%17.66%----

TVTX Forecast FAQ

Is Travere Therapeutics stock a buy?

Travere Therapeutics stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Travere Therapeutics is a favorable investment for most analysts.

What is Travere Therapeutics's price target?

Travere Therapeutics's price target, set by 17 Wall Street analysts, averages $30 over the next 12 months. The price target range spans from $27 at the low end to $33 at the high end, suggesting a potential 101.07% change from the previous closing price of $14.92.

How does Travere Therapeutics stock forecast compare to its benchmarks?

Travere Therapeutics's stock forecast shows a 101.07% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Travere Therapeutics over the past three months?

  • April 2025: 18.75% Strong Buy, 68.75% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 18.75% Strong Buy, 68.75% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 18.75% Strong Buy, 68.75% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.

What is Travere Therapeutics’s EPS forecast?

Travere Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.13, marking a -72.30% decrease from the reported $-4.08 in 2024. Estimates for the following years are $0.6 in 2026, $1.11 in 2027, and $1.88 in 2028.

What is Travere Therapeutics’s revenue forecast?

Travere Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $342.48M, reflecting a 46.88% increase from the reported $233.18M in 2024. The forecast for 2026 is $478.46M, followed by $630.1M for 2027, and $780.85M for 2028.

What is Travere Therapeutics’s net income forecast?

Travere Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-114M, representing a -64.64% decrease from the reported $-322M in 2024. Projections indicate $41.94M in 2026, $117.12M in 2027, and $139.77M in 2028.